Genelux Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Genelux şirketinin toplam hissedar öz sermayesi $33.1M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $40.3M ve $7.2M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$34.06m
Eşitlik	US$33.09m
Toplam yükümlülükler	US$7.18m
Toplam varlıklar	US$40.27m

Son finansal sağlık güncellemeleri

Recent updates

Genelux: H2 2025 PRROC Data Is A Major Inflection Point

Oct 31

We're Keeping An Eye On Genelux's (NASDAQ:GNLX) Cash Burn Rate

Aug 24

We're Hopeful That Genelux (NASDAQ:GNLX) Will Use Its Cash Wisely

Jan 29

We're Not Very Worried About Genelux's (NASDAQ:GNLX) Cash Burn Rate

Sep 27

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: GNLX 'nin kısa vadeli varlıkları ( $36.0M ) kısa vadeli yükümlülüklerini ( $5.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: GNLX şirketinin kısa vadeli varlıkları ( $36.0M ) uzun vadeli yükümlülüklerini ( $1.6M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: GNLX borçsuzdur.

Borcun Azaltılması: GNLX un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: GNLX şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: GNLX serbest nakit akışı her yıl % 36.1 1.1 yıl yetecek nakit akışına sahip olacaktır.

Genelux Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We're Keeping An Eye On Genelux's (NASDAQ:GNLX) Cash Burn Rate

We're Hopeful That Genelux (NASDAQ:GNLX) Will Use Its Cash Wisely

We're Not Very Worried About Genelux's (NASDAQ:GNLX) Cash Burn Rate

Genelux Notifies the Nasdaq Stock Market that it Was Not in Compliance with Nasdaq Listing Rule 5605(c)(2)(A)

Recent updates

Consensus EPS estimates upgraded to US$0.89 loss

Genelux: H2 2025 PRROC Data Is A Major Inflection Point

Price target decreased by 9.6% to US$18.80

Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

Insider recently sold US$200k worth of stock

We're Keeping An Eye On Genelux's (NASDAQ:GNLX) Cash Burn Rate

Consensus EPS estimates upgraded to US$0.88 loss

New major risk - Financial position

Genelux Corporation(NasdaqCM:GNLX) dropped from Russell Small Cap Comp Value Index

Genelux Corporation, Annual General Meeting, Aug 01, 2024

Genelux Corporation has completed a Follow-on Equity Offering in the amount of $27.5 million.

Genelux Corporation has filed a Follow-on Equity Offering.

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.53 loss in 1Q 2023)

Insider recently sold US$256k worth of stock

New minor risk - Market cap size

Price target decreased by 23% to US$26.00

Full year 2023 earnings: EPS and revenues miss analyst expectations

We're Hopeful That Genelux (NASDAQ:GNLX) Will Use Its Cash Wisely

Insider notifies of intention to sell stock

Insider recently sold US$436k worth of stock

Insider recently sold US$210k worth of stock

Insider notifies of intention to sell stock

Insider recently sold US$998k worth of stock

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

We're Not Very Worried About Genelux's (NASDAQ:GNLX) Cash Burn Rate

Genelux Corporation Elects John Smither as Class I Director

Insider recently sold US$879k worth of stock

New major risk - Financial position

Insider recently sold US$489k worth of stock

Genelux Corporation Announces Executive Changes

Chairman recently sold US$198k worth of stock

Chairman notifies of intention to sell stock

New major risk - Share price stability

Genelux Corporation, Annual General Meeting, Sep 11, 2023

Genelux Notifies the Nasdaq Stock Market that it Was Not in Compliance with Nasdaq Listing Rule 5605(c)(2)(A)

Genelux Announces Resignation of Gabe Woodward from the Board

Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Frontiers in Immunology

Genelux Corporation and TVAX Biomedical, Inc. Announces the Issuance of A United States Patent Covering the Combination of an Adoptive T Cell Therapy/Oncolytic Viral Cancer Treatment

Genelux Corporation announced that it expects to receive $33.30494 million in funding

Genelux Corporation has completed an IPO in the amount of $15 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin